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Drug development for Alzheimer’s disease has endeavored to lower amyloid β (Aβ) by either blocking production or 
promoting clearance. The benefit of combining these approaches has been examined in mouse models and shown to 
improve pathological measures of disease over single treatment; however, the impact on cellular and cognitive functions 
affected by Aβ has not been tested. We used a controllable APP transgenic mouse model to test whether combining genetic 
suppression of Aβ production with passive anti-Aβ immunization improved functional outcomes over either treatment 
alone. Compared with behavior before treatment, arresting further Aβ production (but not passive immunization) was 
sufficient to stop further decline in spatial learning, working memory, and associative memory, whereas combination 
treatment reversed each of these impairments. Cognitive improvement coincided with resolution of neuritic dystrophy, 
restoration of synaptic density surrounding deposits, and reduction of hyperactive mammalian target of rapamycin signaling. 
Computational modeling corroborated by in vivo microdialysis pointed to the reduction of soluble/exchangeable Aβ as the 
primary driver of cognitive recovery.
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Introduction
Therapeutic development for Alzheimer’s disease (AD) has 
largely focused on reduction of amyloid β (Aβ) peptide, by 
either inhibiting the enzymes required for Aβ production or 
promoting Aβ clearance using recombinant antibodies. To date, 
all Aβ-lowering clinical trials and most animal model studies have 
tested for functional improvement one approach at a time. Some in 
the field have responded to the limited success of this strategy by 
calling for combination treatments to be tested (Perry et al., 2015; 
Stephenson et al., 2015; Hendrix et al., 2016). This idea is supported 
by the benefits of polytherapy in other complex diseases such as 
cancer, tuberculosis, and HIV/AIDS (Günthard et al., 2016; Bayat 
Mokhtari et al., 2017; Kerantzas and Jacobs, 2017). We and others 
have shown that combination anti-Aβ treatments were better than 
single treatments at limiting plaque formation in mouse models 
of Alzheimer’s amyloidosis (Chow et al., 2010; Wang et al., 2011; 
Jacobsen et al., 2014; Devi and Ohno, 2015). Yet only two of these 
studies initiated treatment after amyloid onset, and neither looked 
at the potential cognitive benefit of this strategy (Chow et al., 2010; 
Wang et al., 2011; Jacobsen et al., 2014; Devi and Ohno, 2015). Thus, 
although there may be mounting interest in multidrug therapy for 
AD, limited preclinical evidence is available to support its promise.
Here we endeavor to fill this knowledge gap. The central 
goal of our study was to test whether better Aβ abatement by 
combining anti-Aβ treatments resulted in better cognitive 
recovery. Secondary to this, we wanted to know what happened 
to neural markers in brain tissue that is cleared of Aβ, and 
further, whether we could identify signaling pathways that 
might connect the recovery of neuronal homeostasis with Aβ 
reduction. Our studies made use of an APP transgenic model in 
which the overexpression of pathogenic APP can be temporally 
controlled with doxycycline (dox; Jankowsky et al., 2005). 
Lowering APP expression in turn lowers Aβ production, and 
thus provides a pharmacogenetic mimic of chemical secretase 
inhibition. Although this is an artificial model, the approach 
avoided the known toxicities of commercially available secretase 
inhibitors that would have prevented prolonged treatment 
(Imbimbo and Giardina, 2011; Golde et al., 2013; De Strooper and 
Chávez Gutiérrez, 2015). Using this controllable APP model, we 
have previously shown that transgene suppression alone halts 
further amyloid formation but, when combined with passive 
anti-Aβ immunization, results in the clearance of up to 50% 
of deposited Aβ from the brain (Wang et al., 2011). Here we 
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examine the impact of plaque removal versus maintenance on 
cognitive performance, cellular pathology, and biochemical 
alterations associated with Aβ accumulation. We then leverage 
this dataset to computationally model the relationship between 
Aβ concentration and behavioral performance with the goal of 
identifying which form of Aβ contributes most strongly to the 
effect of treatment.
Results
Combination therapy removes deposited Aβ and lowers 
soluble Aβ levels in transgenic mice
We used the tet-off APP transgenic mouse as a model for lower-
ing Aβ production after disease onset. The tet-off APP mouse is 
based on the coexpression of two independent transgenes, one 
encoding the tetracycline transactivator (tTA) under control of 
the CaMKIIα promoter, the other encoding mutant APP under 
control of a tTA-responsive promoter. Intercrossing the two 
transgenic lines produces bigenic APP/TTA mice in which dox 
can be used to arrest expression of transgenic APP and subse-
quently reduce Aβ release. Dox treatment of APP/TTA mice thus 
provides a nontoxic chemogenetic mimic of secretase inhibition 
that is safe for long-term use.
Because our goal in the current study was to test whether the 
behavioral effect of Aβ suppression could be improved by add-
ing passive anti-Aβ immunization, we needed to identify an age 
when transgene suppression alone would not fully rescue learn-
ing and memory impairments in this model. We had previously 
shown that short-term suppression of transgenic APP was suf-
ficient to reverse cognitive deficits when started at the earliest 
sign of impairment after 6 mo of transgene expression (Fowler 
et al., 2014). Spatial learning and memory continued to decline 
with ongoing transgene expression (Chiang et al., 2018). By 9 mo, 
behavioral impairments were no longer rescued by the same dox 
treatment that had worked at 6 mo (Fig. S1). This age became the 
starting point for our current study.
Although dox-mediated control of transgenic APP was used 
to lower Aβ production, passive anti-Aβ immunization with 
mouse monoclonal IgG2a antibody Ab9 was used to sequester Aβ 
after its release (Levites et al., 2006a). Aged APP/TTA mice were 
divided into five experimental groups: pretreatment, vehicle, 
dox only, Ab9 only, or dox + Ab9 (Fig. 1 A). A total of 131 APP/
TTA bigenic mice and 19 TTA single transgenic sibling controls 
were used. Mice in the pretreatment group provided baseline 
measures for the APP/TTA model before intervention and were 
used as a standard for comparison of treatment efficacy. All 
remaining animals were injected weekly with Ab9 (500 µg, i.p.) 
or vehicle. Mice in the dox-only and dox + Ab9 groups were fed 
chow containing 100 mg/kg dox. We ascertained by Western 
blot that transgenic APP expression was unchanged by Ab9 or 
vehicle injection but effectively reduced by >95% at this dose 
in both dox-treated groups (Fig. 1 B). The pretreatment group 
was behaviorally tested without treatment and harvested 3 wk 
later. All other groups were behaviorally tested after 9 wk of 
differential treatment and harvested after 12 wk.
We first examined the effect of treatment on plaque burden 
in the brain. Based on past characterization, we expected and 
confirmed that pretreatment animals harbored significant plaque 
pathology throughout the forebrain (44% surface area in cortex 
and 25% in hippocampus as measured by silver staining; Fig. 2, A 
and D; and Fig. S2). Vehicle-treated mice continued to accumulate 
Aβ deposits over the next 12 wk and were harvested with 73% 
of the cortex and 49% of the hippocampus involved. Antibody 
alone had little impact, whereas dox-mediated APP suppression 
maintained plaque load at pretreatment levels (43% cortex and 
23% hippocampus). The combination of dox + Ab9 significantly 
lowered plaque burden by ∼40% relative to pretreatment, leaving 
a footprint of just 26% area in the cortex and 14% in hippocampus 
(see Table S1 for statistics). This change demonstrated that the 
impact of immunotherapy could be amplified by concurrently 
targeting Aβ production, and conversely, that plaque clearance 
occurs only when stimulated by anti-Aβ antibodies.
We next examined the distribution of oligomeric Aβ 
using monoclonal antibody NAB61 (Lee et al., 2006). NAB61 
immunoreactivity occupied considerably less surface area than 
silver stain, but relative differences between treatment groups 
remained. Compared with pretreatment, the vehicle group had 
significantly more NAB61 immunostaining at harvest, whereas 
the dox + Ab9 group had significantly less (Fig. 2, B and E; Fig. 
S2; and Table S1). NAB61 immunoreactivity did not change 
significantly from pretreatment in either monotherapy group. 
Fibrillar amyloid detected by thioflavin-S rose significantly in 
both vehicle and Ab9 groups but was held to pretreatment levels 
in dox-only mice. Unlike the Aβ deposits detected by silver stain 
and NAB61, thioflavin-positive plaques were not reduced by 
combination treatment (Fig. 2, C and F; Fig. S2; and Table S1). 
These results are consistent with past work in younger APP/TTA 
mice and confirm that the chemogenetic arrest of Aβ release 
permits clearance of diffuse deposits but not fibrillar cores 
by concurrent administration of effector-competent anti-Aβ 
antibody (Wang et al., 2011).
In parallel with histological measures of plaque burden, we 
also assessed Aβ concentration by ELI SA in a subset of 15 mice 
from each condition using a three-step extraction method 
(Youmans et al., 2011). The most soluble Aβ extracted into TBS 
was most significantly affected by treatment. Both dox and dox 
+ Ab9 groups had less TBS-soluble total Aβ than pretreatment, 
and within this extract, both Aβ40 and Aβ42 were significantly 
decreased (Fig. S3 and Table S1). No differences in TBS-X 
detergent-soluble Aβ were noted for any treatment group, whereas 
the only significant changes noted in guanidine-soluble Aβ were 
increases in the vehicle and Ab9-only groups, likely indicative of 
elevated fibrillar amyloid in these conditions (Fig. S3).
Recovery of synaptic markers in the plaque boundary area
Exposure to soluble oligomeric Aβ can induce reversible spine 
loss in hippocampal neurons (Calabrese et al., 2007; Lacor et al., 
2007; Shankar et al., 2007), and we were curious to test whether 
synaptic markers would recover with oligomer reduction in vivo. 
Immunostaining for NAB61 suggested that the highest concen-
tration of oligomeric Aβ occurred in immediate proximity to 
fibrillar plaques (Koffie et al., 2009; Chiang et al., 2018), so we 
focused our synaptic marker measurements on a 30-µm zone 
surrounding thioflavin-stained cores.
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We used a custom Matlab script to outline thioflavin 
plaques and measure the area of PSD-95 or synaptophysin 
immunofluorescence in three successive 10-µm-wide annuli. 
Quantification of PSD-95 was hindered by what appeared to 
be glial cells outlined in signal located adjacent to a subset of 
plaques in all treatment conditions (unpublished data). The 
variance in area measure introduced by this labeling made 
quantitation of PSD95 signal unreliable without manually 
selecting plaques for inclusion and exclusion. Synaptophysin 
immunofluorescence was more consistent and could be readily 
measured in an unbiased manner using an automated script. 
Differences between treatment groups were small but steady. 
The area of synaptophysin staining increased with distance from 
the plaque core for all treatment conditions, consistent with the 
idea that synaptotoxic peptide is most concentrated in the zone 
immediately adjacent to the core (Dong et al., 2007; Koffie et 
al., 2009; Dorostkar et al., 2014). Compared with pretreatment, 
however, a persistent increase of synaptophysin signal at all 
distances was observed only for animals treated with dox + Ab9 
(Fig. 3 and Table S1).
Combination treatment lessens axonal swelling and 
rebalances a master lysosomal control
On seeing that combination treatment maximized synaptophysin 
as a marker of synaptic integrity in the area surrounding plaques, 
we wondered whether other neuronal pathologies associated 
with fibrillar Aβ deposits might also be attenuated. Dystrophic 
neurites are prominent in the immediate vicinity of fibrillar 
plaques, swollen with aggregated proteins and interrupted 
vesicles that interfere with electrical transmission and cargo 
trafficking (Knowles et al., 1999; Stern et al., 2004; Tsai et al., 
2004; Stokin et al., 2005). Ubiquitinated proteins accumulate in 
these swellings along with markers of endoplasmic reticulum, 
and ubiquitin or reticulon immunostaining has been used to 
identify dystrophic neurites surrounding amyloid plaques 
(Dickson et al., 1990; Sharoar et al., 2016). Ubiquitin-filled 
neurites formed halos outlining presumptive plaques in APP/
TTA mice before treatment and remained prominent in both 
untreated mice and those given Ab9 alone (Fig. 4 A). Compared 
with pretreatment, the area occupied by ubiquitin immunostain 
was significantly reduced by 32% in dox-treated animals and 
by 41% in mice given dox + Ab9 (Fig.  4, A and B). Similarly, 
LAMP1 is also highly enriched in dystrophic neurites and absent 
in normal adjacent structures, making it a good marker for 
detection of axonal swellings (Condello et al., 2011, 2015). LAMP1 
immunofluorescence consistently surrounded thioflavin-S+ 
amyloid cores in pretreatment animals. Compared with 
pretreatment, the extent of LAMP1 staining was reduced by 64% 
in mice given dox + Ab9 (Fig. 4, C and D; and Table S1). The area 
of LAMP1 immunostaining across the cortex was also lowered 
by dox alone, but the difference did not reach significance. 
These findings suggest that by removing diffuse aggregates of 
extracellular Aβ, pathological accumulation of intraneuronal 
protein can also be dismantled.
Figure 1. Experimental design comparing the outcome of no treatment, passive immunization, transgene suppression, or both against performance 
before intervention. (A) APP/TTA mice expressed transgenic APP for 9 mo (from 1.5 until 10.5 mo of age) before being divided into five experimental groups. 
Animals in the pretreatment group underwent immediate behavioral testing without intervention to measure baseline performance (n = 24). All other animals 
were treated for 12 wk with one of the following: vehicle (n = 28), Ab9 anti-Aβ antibody (n = 26), dox (n = 27), or dox + Ab9 (n = 26). Behavioral testing began 
9 wk into each treatment and continued until animals were harvested for histological and biochemical analysis. (B) Western blot probed with human-specific 
antibody 6E10 confirmed effective transgene suppression in the dox-treated groups. Graph shows quantitation of APP signal relative to GAP DH for each lane 
and normalized to the pretreatment group mean. Error bars show means ± SEM.
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Upstream of LAMP1, lysosomal biogenesis is regulated by the 
transcription factor EB (TFEB; Sardiello et al., 2009; Settembre et 
al., 2011). Accumulation of lysosomal proteins such as LAMP1 is 
consistent with defective autophagy in AD (Nixon, 2007; Nixon 
and Yang, 2011), and increased levels of TFEB have been docu-
mented in aged APP/PS1 mice (Zhang and Zhao, 2015). We found 
that unlike LAMP1, TFEB immunostaining labeled cells broadly 
across the cortex. The signal appeared to be cytoplasmically 
localized in all treatment conditions but less intensely stained in 
tissue from mice treated with dox or dox + Ab9 (Fig. 4 E). We con-
firmed this difference by Western blotting. Cortical expression of 
TFEB was elevated roughly 50% in pretreatment APP/TTA mice 
compared with TTA single transgenic siblings. TFEB expression 
was diminished by dox alone, but only dox + Ab9 reached signif-
icance versus pretreatment (Fig. 4, F and G; and Table S1).
Aberrant mTOR signaling as a common mediator of neuronal 
pathology rescued by combination therapy
Although innumerable signaling pathways have been implicated 
downstream of Aβ, the mTOR pathway stood out as a media-
tor capable of influencing both synapse density and lysosomal/
autophagy function via a complex network of effector proteins 
(Garza-Lombó and Gonsebatt, 2016). mTOR hyperactivity has 
been detected in human AD brains and APP transgenic mice and 
can be induced by Aβ in wild-type mice (An et al., 2003; Griffin 
et al., 2005; Caccamo et al., 2010, 2011). We wondered whether 
hyperactive mTOR signaling might contribute to the synaptic and 
cellular phenotypes of untreated APP/TTA mice, and whether 
treatment would restore normal activity through this pathway. 
We used the phosphorylation of downstream target S6 ribosomal 
protein (p-S6s420/244) as a readout for raptor-dependent mTORC1 
Figure 2. Transgene suppression stopped further plaque formation; adding anti-Aβ antibody promoted plaque clearance. (A) Sagittal sections stained 
by the Campbell–Switzer method reveal total plaque load in each treatment condition. Bottom row shows higher-magnification images centered on hippocampus 
and overlying cortex. Bars: (top row) 2,000 µm; (bottom row) 500 µm. (B) NAB61 immunofluorescence for oligomeric Aβ in dorsal hippocampus and overlying 
cortex. Gray lines indicate location of pial surface and corpus callosum. Bar, 500 µm. (C) Thioflavin-S stain for fibrillar amyloid in dorsal hippocampus and 
overlying cortex. Bar, 500 µm. (D–F) Quantification of cortical plaque area: CS silver (D), NAB61 (E), and thioflavin-S (F). Dashed line in scatter plots indicates 
the pretreatment plaque load for each stain. Significant comparisons against pretreatment or between dox and dox + Ab9 are shown; other comparisons are 
listed in Table S1. n = 9–11/group. **, P < 0.01; ****, P < 0.0001; #, P = 0.09. Error bars show means ± SEM.
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activity and AKT/protein kinase B (p-AKTs473) as a readout for 
rictor-dependent mTORC2 activity (Hoeffer and Klann, 2010; 
Costa-Mattioli and Monteggia, 2013). Immunoblotting of hippo-
campal extracts revealed a modest 1.5-fold increase of mTORC1 
activity in pretreatment compared with TTA controls (Fig. 5, A and 
B), alongside an eightfold increase of mTORC2 activity (Fig. 5, C 
and D). The activity of both complexes was restored to control 
levels in mice treated with dox + Ab9 (Fig.  5, A–D; and Table 
S1). mTOR activity was nonsignificantly reduced in dox-treated 
animals and was unchanged in mice given vehicle or Ab9 alone.
mTORC2 signaling is known to regulate spine turnover in the 
adult brain via cofilin-dependent stabilization of synaptic actin. 
We explored this connection by immunoblotting hippocampal 
extracts for mTORC2-depedent cofilin phosphorylation (p-co-
filins3; Huang et al., 2013). We detected hyperphosphorylation 
in the pretreatment group—consistent with elevated mTORC2 
activity—that was significantly decreased in mice receiving 
either dox or dox + Ab9 and restored to the level of TTA controls 
in the latter group (Fig. 5, E and F; and Table S1). Thus, mTOR 
activity may mediate both the synaptic recovery (via mTORC2) 
and the resolution of lysosomal blockade (via mTORC1) that 
accompany cognitive recovery by combination therapy.
Combination treatment rescues cognitive function in aged 
transgenic mice
Our analyses so far showed that combination anti-Aβ therapy 
cleared diffuse amyloid, increased synapse area, resolved neu-
ritic dystrophy, and normalized mTOR signaling. However, the 
primary goal of our study was to determine whether these effects 
of combined anti-Aβ treatment supported a better behavioral 
outcome than single interventions. To address this question, 
all animals underwent behavioral testing starting 9 wk into the 
12-wk treatment period to measure the cognitive impact of each 
strategy. TTA single transgenic siblings were included as controls 
and were given either vehicle or dox + Ab9 on the same sched-
ule as APP/TTA mice. We observed no significant differences 
between these two TTA treatment groups for any outcome mea-
sure (unpublished data), and so they were combined for illus-
tration here. All animals underwent basic locomotor assessment 
before cognitive testing and visual acuity testing afterward; no 
significant impairments were detected in any group (Fig. S4).
Cognitive testing consisted of three tasks performed in suc-
cession to examine different aspects of hippocampal-dependent 
learning and memory. Testing began with a train-to-criteria 
version of the Morris water maze (MWM) that measured spatial 
Figure 3. Synaptic recovery surrounding amyloid cores after combination anti-Aβ treatment. (A) Synaptophysin immunofluorescence (red) was measured 
in a zone immediately surrounding fibrillar plaques identified by thioflavin-S (green; top row). A magnified portion of the synaptophysin immunofluorescence 
(outlined in top row) is shown at higher magnification in the bottom row of images. Bars: (top row) 50 µm; (bottom row) 20 µm. (B) Illustration of image 
processing for area quantitation. Raw fluorescence images were converted to black and white for each color channel. The thresholded thioflavin image was used 
to outline the plaque, and this outline was expanded to delineate concentric rings that were applied to the thresholded synaptophysin image. (C and D) The area 
of synaptophysin staining was measured in concentric rings 0–10, 10–20, and 20–30 µm from the plaque edge. Graphs show individual scatter (C) and group mean 
(D) at each distance. Significant comparisons against pretreatment are shown; other comparisons are listed in Table S1. n = 9–11/group. *, P < 0.05; **, P < 0.01; 
***, P < 0.001; ****, P < 0.0001. Error bars show means ± SEM.
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reference learning and memory. This was followed by radial 
arm water maze (RAWM) to measure working memory and 
ended with contextual fear conditioning (FC) to measure asso-
ciative memory. In each of these tasks, performance of the pre-
treatment group was markedly impaired compared with TTA 
controls, confirming that the APP/TTA mice displayed substan-
tial cognitive deficits before intervention (Fig. 6, A, C, and D). 
The comparisons in which we were most interested, however, 
were not between genotypes but between treatment condi-
tions, and specifically between the pretreatment and post-
treatment groups. From this perspective, only mice given dox 
+ Ab9 improved significantly across all three tasks compared 
with pretreatment performance, as described in detail below 
(Fig. 6, A–D; and Table S1).
We chose a train-to-criteria version of MWM so that we could 
distinguish learning from recall, and where relevant, test treat-
ment effects on both. In this task, the rate of learning is mea-
sured by the number of days required to reach a preset perfor-
mance level in probe trials conducted at the end of each training 
session. Dox + Ab9 was the only posttreatment group that took 
significantly fewer days to reach criterion performance than pre-
treatment (Fig. 6 A and Table S1). Despite their residual fibrillar 
pathology, dox + Ab9 mice learned this task as quickly as TTA 
controls. Dox + Ab9 was also the only group that showed faster 
Figure 4. Therapeutic reduction of extracellular Aβ allowed clearance of intraneuronal pathology. (A) Representative images of ubiquitin immunohisto-
chemistry for dystrophic neurites. Top row shows immunostaining in cortex and dorsal hippocampus at low magnification. Higher-magnification images (bottom 
row) show a single neuritic plaque to illustrate the remediation of neuritic swellings with dox and dox + Ab9 treatment. Bars: (top row) 500 µm; (bottom row) 
50 µm. (B) Quantification of ubiquitin immunostaining as percent of cortical surface area. Dashed line indicates mean area of ubiquitin signal in pretreatment 
animals. (C) Representative immunofluorescence for the lysosomal marker LAMP1. Top row shows immunostaining in cortex and dorsal hippocampus at low 
magnification. Gray lines indicate rough location of pial surface and corpus callosum. Higher-magnification images (bottom row) show LAMP1 signal surround-
ing a single representative plaque in each condition. Bars: (top row) 500 µm; (bottom row) 50 µm. (D) Quantification of LAMP1 immunostaining as percent 
of cortical surface area. Dashed line indicates mean area of LAMP1 signal in pretreatment animals. (E) TFEB immunofluorescence (red) was not localized to 
plaques but appeared diffusely throughout the cortex, with lower signal intensity in dox and dox + Ab9 groups. Bar, 50 µm. (F) Representative Western blot 
for hippocampal TFEB expression. (G) Quantification of TFEB Western blots, expressed relative to GAP DH n = 8/group (3 for TTA). Dashed line in scatter plot 
indicates normalized mean TFEB expression in TTA control animals. TTA values in this and subsequent figures are for illustration only; statistical comparisons 
included only APP/TTA groups. Post hoc comparisons against pretreatment are shown; other post hoc comparisons are listed in Table S1. n = 9–11/group for 
histological analysis and n = 8/group for protein analysis. *, P < 0.05; **, P < 0.01; ****, P < 0.0001; #, P = 0.054. Error bars show means ± SEM.
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improvement than pretreatment in their recall accuracy for the 
platform location during end-of-day probe trials (Fig. 6 B). In 
contrast, animals given dox alone appeared to be better than pre-
treatment, but post hoc comparisons never reached significance. 
This distinction suggests that dox + Ab9 afforded some functional 
benefit for spatial learning over dox alone, albeit not sufficient to 
reach statistical significance.
Once all mice in the testing group reached criteria perfor-
mance in the MWM, the entire cohort was given refresher train-
ing and then tested for long-term memory 24 h later. This design 
ensures that all mice are at the same performance level before 
testing long-term spatial memory. Even at this advanced stage 
of pathology, we found no differences in long-term memory 
between genotypes (APP/TTA vs. TTA) or between treatment 
groups (Fig. S4 and Table S1). This outcome indicates that the 
primary spatial deficit of APP/TTA mice at this age is in learning 
and not recall.
We then reconfigured the pool to a six-arm radial maze as a 
1-d test of working memory (modified from Alamed et al., 2006). 
In this task, incorrect arm entries represent an error of working 
memory, and the number of errors should decrease over succes-
sive trials as animals learn the maze (Fig. 6 C). The total number 
of arm entry errors for the day therefore serves as an aggregate 
measure of learning for this task. Compared with the pretreat-
ment group, total entry errors was significantly reduced only for 
mice receiving dox + Ab9 (Fig. 6 C and Table S1).
We also examined the effect of anti-Aβ treatment on contextual 
FC. In this task, associative memory for an environment in 
which animals were mildly foot-shocked can be measured by 
the percentage of time they spend immobile when returned to 
the chamber the next day. Consistent with the findings from 
MWM and RAWM, only the dox + Ab9 group spent significantly 
more time immobile in the trained context than pretreatment 
(Fig. 6 D and Table S1).
Of note, mice given Ab9 or dox alone showed no significant 
improvement from pretreatment in any task (Fig. 6, A–C). Animals 
given dox alone showed a trend toward improvement in MWM 
and RAWM, but post hoc comparisons against pretreatment 
performance never reached significance. Because performance of 
the dox group against pretreatment often approached significance 
but always failed to reach P < 0.05 after adjustment for multiple 
comparisons, we were curious whether direct assessment of 
dox versus dox + Ab9 might support or refute the benefit of 
combination treatment. We wanted this analysis to capture overall 
performance and so used a multivariate ANO VA that incorporated 
behavioral outcomes from each task: days to criteria in MWM, 
total errors in RAWM, and percentage of time immobile in FC. 
This comparison of aggregate behavioral performance between 
dox and dox + Ab9 demonstrated a significant difference between 
groups (multivariate ANO VA, Wilk’s Λ = 0.812, partial η2 = 0.19; 
Table S1). On the whole, animals receiving combination therapy 
had indeed outperformed those receiving dox alone.
Figure 5. Hyperactive mTOR signaling was normalized by combination anti-Aβ treatment. (A and B) Representative Western blots and quantitation for 
hippocampal mTORC1-dependent phosphorylation of S6 ribosomal protein. (C and D) Western blots and quantitation for mTORC2-dependent phosphorylation 
of protein kinase B, also known as Akt. Note the y-axis scale in D, reflecting the dramatic elevation of mTORC2 activity in pretreatment APP/TTA mice compared 
with TTA controls. (E and F) Western blots and quantitation for cofilin phosphorylation downstream of mTORC2. Measurements are expressed as a ratio of 
phosphorylated to total protein for each marker. n = 8/group (6 for TTA). Dashed line in scatter plots indicates normalized mean expression in TTA control 
animals. Comparisons against pretreatment are shown; other post hoc comparisons are listed in Table S1. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars 
show means ± SEM.
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Reduction of soluble Aβ corresponds with improved 
behavioral performance
We realized that the dataset generated from our study might 
allow us to identify which forms of Aβ were most highly cor-
related with behavioral impairment across treatments and there-
fore would be most important to target for functional recovery. 
We began by examining simple Pearson correlations between the 
six Aβ concentrations measured by ELI SA for each animal (Aβ 
40 and 42 measured from TBS, TBSX, and guanidine extracts) 
and the four representative behavioral measures from MWM, 
RAWM, and FC. The behavioral outcomes included (a) MWM 
total daily mean path length to the platform during training, a 
continuous variable reflecting the rate at which animals learned 
the escape location; (b) MWM day 2 probe proximity, reflecting 
short-term memory performance on the final day that all animals 
were still in training; (c) RAWM mean errors, reflecting working 
memory performance, and (d) FC mean percentage time immo-
bile, reflecting associative recall performance. Pearson testing 
revealed nominally significant correlations between Aβ concen-
tration and the two spatial navigation tasks (MWM and RAWM) 
but found no significant relationship between Aβ and FC for 
either peptide in any extract (Table S1). We used these results to 
focus computational modeling on MWM and RAWM performance 
as a function of Aβ concentration in each animal. General linear 
models for MWM or RAWM outcomes were built with all six Aβ 
measures as possible independent variables, using forward and 
backward stepwise selection to minimize the Akaike information 
criterion. This unbiased optimization resulted in models that 
consistently included either TBS Aβ40 or TBS Aβ42 (which were 
highly collinear), along with one other nonoverlapping variable. 
Figure 6. Cognitive deficits in aged APP/TTA mice were rescued by combination anti-Aβ treatment. (A) Mean number of training days to reach criteria 
performance in the MWM. (B) Proximity to trained location during MWM daily probe trials, plotted for the mean number of days to criteria performance for each 
group (left). Statistical comparison of improvement in MWM probe proximity between groups was tested for days 1–2 of training (right). (C) RAWM performance 
plotted as mean reentry errors per group (left) or by trial (right). (D) Percentage of time immobile during recall of contextual fear plotted as overall mean per 
group (left) or by minute (right). Dashed line in scatter plots of A, C, and D indicates mean performance of age-matched TTA mice. TTA values shown here are 
combined for vehicle and dox + Ab9 treatment and are not included in statistical comparisons of APP/TTA treatment groups. n = 24–28/group (19 for TTA). 
*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Error bars show means ± SEM.
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In one case, this second variable did not contribute significantly 
to the final equation; in another it contributed negatively to the 
correlation. We therefore focused subsequent modeling on test-
ing the extent to which TBS Aβ alone accounted for MWM and 
RAWM performance. Remarkably, we found that models based 
solely on total TBS Aβ fitted the behavioral data as well as the ini-
tial multivariate equations. Further graphical examination of the 
model residuals suggested that the relationship between behav-
ior and TBS Aβ may be nonlinear. Each computational model was 
then modified to include a polynomial term. This modification 
substantially improved the fit between predicted and actual out-
comes. The resulting models defined behavioral outcome as a 
function of total TBS Aβ with the following terms: y = intercept 
+ a × [TBS Aβ] + b × [TBS Aβ]2. This simple equation accounted for 
38% of the variance in MWM total path length, 31% of variance 
in MWM spatial recall accuracy, and 47% of variance in RAWM 
working memory errors (Fig. 7, A–D; and Table S1). These mod-
els predict that a relatively small fraction of highly soluble Aβ 
explains an unexpectedly large proportion of the variation in 
cognitive performance between animals.
We then returned to the mice to ask whether the situation in 
vivo supported the emphasis placed on soluble Aβ by our theo-
retical models. Based on our models, we expected that the subtle 
improvement in behavioral performance between dox and dox + 
Ab9 mice arose in large part from a reduction of free Aβ in the 
brain. We used in vivo microdialysis to measure exchangeable Aβ 
in the interstitial fluid from a subset of dox and dox + Ab9 mice 
after they completed behavioral testing. A microdialysis probe 
with a 1 MDa cutoff size was chosen to capture all soluble Aβ 
species from monomeric peptide to large oligomers. Interstitial 
Aβ concentrations were 39% (Aβ40) and 37% (Aβ42) lower in mice 
given dox + Ab9 than in mice treated with dox alone (Fig. 7 E and 
Table S1), suggesting that combination treatment provided better 
in vivo control over behaviorally relevant forms of Aβ than APP 
suppression alone.
Discussion
We set out to test whether combining multiple complementary 
methods for Aβ reduction would improve cognitive function 
in amyloid-bearing transgenic mice compared with individ-
ual treatments alone. We demonstrate that combining passive 
anti-Aβ immunization with chemogenetic arrest of new Aβ pro-
duction restored the cognitive performance of mice with severe 
amyloid to that of healthy age-matched controls. Computational 
modeling corroborated by in vivo microdialysis indicates that the 
combined treatment exerted its primary effect through reduction 
of soluble/exchangeable Aβ species. Consistent with this conclu-
sion, thioflavin-positive fibrillar amyloid was unchanged from 
pretreatment, yet behavioral performance was consistently bet-
ter after dox + Ab9. This outcome suggests that the mouse brain 
can tolerate the continued presence of fibrillar plaque cores 
while reestablishing effective circuits for learning and memory, 
provided the soluble peptide load is sufficiently reduced. Effec-
tive targeting of soluble Aβ was accompanied by attenuation of 
mTOR hyperactivity and, with it, a potential mechanistic link 
to the recovery of synaptic markers and resolution of neuritic 
swellings supporting functional improvement.
Figure 7. TBS-soluble Aβ emerged as the primary driver of behavioral performance. (A–D) MWM and RAWM performance modeled as a function of total 
cortical TBS-soluble Aβ. Values are plotted for every animal in which Aβ concentration was measured by ELI SA after behavioral testing. Treatment groups are 
color coded: pretreatment (white), vehicle (black), Ab9 (blue), dox (red), dox + Ab9 (green). (A) Total daily mean distance to the platform (m) for all days of MWM 
training as a function of AβTBS. Both linear (dotted line) and polynomial models (solid line) are shown for this dataset. R2 values improved substantially with the 
addition of a second-order term. (B) Proximity to the trained location on the day 2 probe trial as a function of AβTBS. (C) Mean arm reentry errors during trials 
2–8 in RAWM as a function of AβTBS. (D) Polynomial equations graphed in A–C. (E) Hippocampal ISF Aβ40 and Aβ42 measured by microdialysis in a subset of 
behaviorally tested mice (n = 6–7/group for Aβ40, n = 4–5/group for Aβ42). *, P < 0.05; **, P < 0.01. Error bars show means ± SEM.
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Although prior work had suggested the involvement of mTOR 
dysregulation in AD, we did not expect to find mTORC2 activity 
elevated by eightfold in APP/TTA mice before treatment. mTORC1 
activity was less markedly elevated than mTORC2, but both were 
restored to control levels in mice treated with dox + Ab9. mTOR 
is a pleiotropic signaling protein, and its impact on diverse 
downstream targets could contribute to multiple pathological 
phenotypes in APP/TTA mice. Normal mTOR function is critical 
for several forms of synaptic plasticity as well as spatial and 
contextual memory (Costa-Mattioli and Monteggia, 2013; 
Bockaert and Marin, 2015). Genetic elevation of mTOR activity 
in mouse models of tuberous sclerosis was sufficient to impair 
spatial learning and contextual discrimination while lowering 
the threshold for synaptic potentiation; in turn, pharmacologic 
intervention with rapamycin rescued cognitive behavior and 
synaptic sensitivity, suggesting that mTOR hyperactivity was also 
necessary for these phenotypes (Ehninger et al., 2008). Elevated 
mTOR signaling has been observed in AD and Down syndrome 
as well as in APP/tau transgenic models and Aβ-treated primary 
neurons, where genetic reduction of mTOR or its downstream 
targets—or pharmacologic intervention with rapamycin—
attenuated synaptotoxicity, restored synaptic protein markers, 
and rescued cognitive impairment pointing toward a causal role 
in these features of disease (Oddo, 2012; Talboom et al., 2015; 
Di Domenico et al., 2018). Beyond the synapse, mTOR signaling 
governs basic cellular homeostasis and negatively regulates 
autophagy (Saxton and Sabatini, 2017). Consistent with this 
role, hyperactive mTOR signaling was shown to cause autophagic 
arrest in models of AD and other proteinopathies where genetic 
or pharmacologic mTOR suppression restored autophagic flux 
and promoted degradation of intraneuronal aggregates (Berger 
et al., 2006; Crews et al., 2010; Roscic et al., 2011; Caccamo et al., 
2013). Based on this evidence, we predict that the broad rescue 
of synaptic markers, cognitive function, and cellular homeostasis 
afforded by dox + Ab9 treatment here was mediated in large part 
by its effect on mTOR signaling. This hypothesis would be ideally 
tested by inducible CNS-specific mTOR knockdown, but might be 
more quickly, if less cleanly, examined with chronic rapamycin 
treatment in future experiments.
The dataset generated here allowed us to test whether and 
how behavioral performance in our mice depended on brain 
Aβ concentration. We uncovered three key findings from these 
analyses. First, we found that cortical Aβ levels had a strong 
and significant influence on performance in the two spatial 
navigation tasks, MWM and RAWM, but no impact on associa-
tive memory of contextual information in FC. This discrepancy 
may be explained by greater reliance on brain areas such as the 
amygdala in FC that were not tested for Aβ (Maren et al., 2013; 
Herry and Johansen, 2014) or may indicate that performance in 
this task is not dependent on Aβ load. Despite the lack of cor-
relation between cortical Aβ and FC performance, combination 
treatment nevertheless produced significant improvement in 
this task, as it had for MWM and RAWM. The second key finding 
from the statistical modeling was the importance of soluble Aβ 
in governing performance on spatial tests of cognitive function. 
Past work had shown that exogenous application of oligomeric 
Aβ impaired synaptic plasticity and spatial learning in wild-type 
rodents (Walsh et al., 2002; Cleary et al., 2005; Shankar et al., 
2008). Conversely, passive immunization with anti-oligomer 
antibody was sufficient for cognitive protection in 3xTg-AD mice 
(Rasool et al., 2013), whereas the efficacy of broad-spectrum IV 
immunoglobulin depended on its reduction of oligomeric Aβ in 
Dutch APP mice (Knight et al., 2016). Of note, a subset of Dutch 
APP mice developed cognitive deficits in the absence of deposited 
plaques, supporting the idea that soluble Aβ species are sufficient 
for functional impairment. Indeed, the presence or absence of 
oligomeric Aβ was sufficient to explain the observed bimodal 
distribution in MWM days to criteria in this model (Gandy et al., 
2010). Here we build on that approach, applying multivariate 
statistical modeling of Aβ solubility, species, and concentration 
to explain individual variation in behavioral performance. This 
analysis confirmed prior work suggesting that the small amount 
of mobile Aβ in soluble form has a disproportionate influence on 
cognitive performance compared with the much larger concen-
tration of Aβ held in fibrillar plaques (Dodart et al., 2002; Zhang 
et al., 2011; Fowler et al., 2014; Liu et al., 2015). Thus, although 
lowering plaque burden is a quantifiable therapeutic goal, the 
commensurate reduction of soluble peptide may actually have 
greater impact on neural function. Finally, the third important 
outcome of our statistical modeling was the discovery that the 
relationship between soluble Aβ and spatial cognition was non-
linear. This nonlinearity may reflect a biological mechanism such 
as receptor saturation at high Aβ concentration, or may simply 
arise from limits on the range of our behavioral assays. We con-
sider both explanations likely, but suspect the limits of our assays 
and the behavioral range of mice in general had a bigger hand in 
shaping this result. Performance was more tightly defined by this 
relationship at low concentrations and became more variable as 
soluble Aβ increased.
Although straightforward in concept, testing combination 
anti-Aβ strategies in mice requires several approximations 
in practice to overcome known limitations of the available 
inhibitors and the animal models. One technical issue we faced 
with our APP/TTA transgenic model was the inability to use 
commercial secretase inhibitors that would have more closely 
approximated a multidrug regimen for clinical use. Existing 
γ-secretase inhibitors such as DAPT (Dovey et al., 2001), LY411575 
(Wong et al., 2004), or LY450139/semagacestat (Siemers et al., 
2005) are poorly tolerated for chronic use because of their side-
effect profile (Imbimbo and Giardina, 2011; Golde et al., 2013; 
De Strooper and Chávez Gutiérrez, 2015), whereas β secretase 
inhibitors such as LY2811376 (May et al., 2011) are ineffective 
at normal dosage against transgenic APP encoding the Swedish 
mutation (unpublished data). We instead took advantage of the 
tet-transactivator system to lower Aβ production by arresting 
expression of transgenic APP. This genetic approach comes 
with its own caveats. APP overexpression can have behavioral or 
biochemical effects beyond those resulting from Aβ, raising the 
possibility that improvements seen with treatment were caused 
simply by suppressing these artifacts. We cannot eliminate 
this possibility; however, several lines of evidence mitigate its 
likelihood. First, the temporal dynamics of APP suppression 
and behavioral/biochemical recovery were markedly different. 
Maximal transgene suppression was attained within 4 d of 
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dox onset, yet cognitive function was still impaired after 2-wk 
dox treatment and remained statistically unchanged from 
pretreatment after 12 wk on dox. Second, the extent of behavioral 
recovery attained by dox treatment in APP/TTA mice was 
markedly different at 9 mo than it had been at 6 mo (Fowler et al., 
2014), despite equal transgene suppression at both ages. When 
dox was initiated after 6 mo of APP overexpression, performance 
in all three tasks was restored to the level of healthy controls 
within 2–5 wk of treatment. When treatment was started at 9 mo 
here, only total errors in RAWM met this standard and only after 
9–12 wk on dox. The difference in cognitive recovery observed 
at 6 and 9 mo may be explained by a difference in the extent of 
tissue damage present before treatment, but this damage is more 
likely caused by the rising Aβ burden than ongoing exposure to a 
steady concentration of other APP fragments.
The transgenic system we used to model chronic suppres-
sion of Aβ release may also underlie the pronounced difference 
in effect size between the individual treatments tested here. We 
suspect that the substantial amount of Aβ continuously pro-
duced in the APP/TTA model simply overwhelmed the binding 
capacity of anti-Aβ antibody. This mouse model overexpresses 
transgenic APP at levels ∼10-fold higher than the endogenous 
protein and incorporates the Swedish mutation to increase pro-
cessing through the β-secretase pathway (Jankowsky et al., 2005; 
Rodgers et al., 2012). Transgene suppression with dox treatment 
thus interrupts a large pipeline of Aβ release with >95% efficacy. 
In contrast to dox treatment, which controls Aβ at the level of 
production synthesis, anti-Aβ antibody sequesters Aβ after it is 
released, capturing at most two peptides for every molecule of 
antibody. The efficacy of Ab9 is limited by three additional fac-
tors that do not affect dox treatment. First, very little antibody 
actually reaches the brain where most Aβ resides. The steady-
state level of peripherally administered antibody within the CNS 
is estimated to be less than 0.1% of the total dose (Bard et al., 
2000; Levites et al., 2006b; Golde et al., 2009). Second, once free 
antibody encounters Aβ, the resulting antigen–antibody complex 
is quite stable, essentially rendering the bound antibody inactive 
(DeMattos et al., 2001; Levites et al., 2006b). Finally, Ab9 recog-
nizes an epitope that Aβ shares with APP (Levites et al., 2006a), 
diverting antibody that does reach the brain from engaging 
peptide. In principle, some of these limitations might have been 
overcome by increasing the dose of Ab9; however, at 500 µg/wk, 
the mice were already at the limit of what has been used in past 
animal studies (Hartman et al., 2005; Levites et al., 2006a) and 
equivalent to high-dose anti-Aβ antibody in current human clini-
cal trials (i.e., 1,200 mg gantenerumab/∼125-lb subject ≅ 20 µg/g, 
for a 25 g/mouse = 500 µg). That this dose of anti-Aβ antibody 
which had little effect alone was sufficient to improve all out-
comes when used in conjunction with Aβ suppression is partic-
ularly encouraging given the likelihood that few secretase inhibi-
tors will lower Aβ production to the same degree as dox-mediated 
transgene suppression.
We hope that this study will prompt serious consideration 
of multidrug trials for Aβ reduction in AD. Our results indicate 
the reduction of soluble/exchangeable Aβ as a critical factor in 
cognitive efficacy and suggest that the removal of deposited 
peptide is beneficial only inasmuch as it eliminates a vast supply 
of loosely associated Aβ in exchange with the surrounding 
extracellular fluid. Whether mTOR mitigation is a marker 
or mechanism of the intracellular recuperation effected by 
combination therapy remains to be proven; nevertheless, it 
offers a provocative but testable candidate for future multidrug 
cocktails in animal models of AD.
Materials and methods
Mice
Mice expressing transgenic APPswe/ind under control of the tTA 
promoter (tetO-APPswe/ind line 102; Jankowsky et al., 2005) 
were mated to mice expressing tTA under control of the CaM-
KIIα promoter for these studies (CaMKIIα-tTA line B; 3010; Jack-
son Laboratory; Mayford et al., 1996). Each line had been inde-
pendently backcrossed to C57BL/6J for >25 generations before 
being intercrossed. APP/TTA double transgenic B6 males were 
subsequently mated with wild-type FVB females to produce 
experimental F1 cohorts. Both male and female animals were 
used for experiments, balanced across treatment groups. All 
experiments involving live mice were reviewed and approved by 
the Institutional Animal Care and Use Committee of Washington 
University School of Medicine (in vivo microdialysis) or Baylor 
College of Medicine (all other experiments).
Dox administration
All mice used in this study were reared on dox from shortly after 
birth until postnatal day 42 (P42) to suppress APP transgene 
expression during postnatal development (Rodgers et al., 2012). 
Offspring were started on dox 1–3 d after birth by placing nurs-
ing mothers on medicated chow (100 mg/kg dox in Purina 5058 
chow; F6712; BioServe). After weaning at P21, mice were main-
tained on dox until P42 (100 mg/kg dox in Purina 5001 chow; 
F6619; BioServe). At P42, mice were switched to standard Purina 
5001 chow and remained on this diet until 10.5 mo of age, when 
animals were divided into treatment groups before behavioral 
testing. At that time, two groups were returned to dox chow (dox, 
dox + Ab9; F6619); other groups remained on standard diet.
Short-term APP suppression
To test the reversibility of cognitive deficits after short-term APP 
suppression, one cohort of 10.5-mo-old APP/TTA mice (allowing 
9 mo of transgenic APP expression, as described above) was 
treated with dox chow (F6619) for 2 wk before behavioral testing 
and was maintained on dox until harvest.
Antibody injections
1 wk after starting on dox chow, mice received the first of 12 
weekly i.p. injections containing either 500 µg purified anti-Aβ1-16 
monoclonal antibody Ab9 (Levites et al., 2006a; Wang et al., 2011) 
diluted in DMEM–high glucose + 10% chemically defined medium 
for high-density cell culture or vehicle (0.9% saline).
Behavioral assays
Behavioral testing began at 10.5 (pretreatment), 11 (acute dox sup-
pression), or 13 mo of age (vehicle, Ab9, dox, and dox + Ab9), after 
at least 9 mo of transgenic APP expression in the APP/TTA animals 
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(or longer for vehicle and Ab9 groups). The behavioral battery is 
described in detail in Fowler et al., 2014. Animals were handled for 
3 d before the start of behavioral testing. Open field assay began 
on day 1, followed by MWM training on days 2–12, RAWM training 
on day 13, and visible cue testing on day 14. Animals underwent 
FC training on day 16, with a context test 24 h later. Because the 
behavioral experiments spanned ∼150 mice, testing was sepa-
rated into 13 experimental cohorts (∼12 animals per cohort). This 
group size ensured that the intertrial interval during training was 
similar for every animal. Each cohort included mice from all five 
treatment groups and at least one of two TTA controls. All animal 
experiments were reviewed and approved by the Baylor College 
of Medicine Institutional Care and Use Committee.
Visible cue testing
Although included in our earlier behavioral studies of APP/TTA 
mice (Fowler et al., 2014), the procedure for testing visual acuity 
was not described in detail. After completion of RAWM testing, 
visible cues were removed from the walls and the escape platform 
and were replaced by one marked with a pole bearing black tape 
that protruded 10 cm from the water surface. The platform was 
moved in random order between the four quadrant locations, and 
animals were placed into the pool directly opposite the platform 
for each trial. Animals were given 60 s to locate the platform and 
returned to their home age for 15 min between trials. Animals had 
to remain on the platform for at least 5 s to count as a successful 
trial, and were required to locate and remain on the platform for 
three of the four trials; animals that failed two or more trials were 
excluded (pretreatment, one APP/TTA; Ab9 only, two APP/TTA).
Contextual FC
Movement was recorded by a video camera counted inside the 
chamber and analyzed using Video Freeze software (Med Asso-
ciates). Motion threshold was set to 19 arbitrary units, and the 
minimum freeze to 1 s. During training on the first day, mice were 
allowed to freely explore the chambers for 80 s before receiving a 
2-s, 0.8-mA foot shock. Mice received two more 2-s, 0.8-mA foot 
shocks at 180 and 240 s and were returned to their home cage 60 s 
after the final shock. The next day, animals were returned to the 
conditioning chamber for a 5-min retention test. The duration of 
immobility was recorded and used as an index of recall.
Tissue harvest
1 d after behavioral testing ended, mice were killed by sodium 
pentobarbital overdose and transcardially perfused with PBS + 
heparin. Brains were removed and hemisected along the midline. 
The cortex and hippocampus of the left hemisphere were snap-
frozen on dry ice and stored at −80°C; the right hemisphere 
was immersion-fixed in 4% PFA at 4°C for 48  h. Brains were 
cryoprotected in 30% sucrose at 4°C. Tissue was sectioned at 35 
µm in the sagittal plane using a freezing sliding microtome and 
stored in cryoprotectant at −20°C until use.
Campbell–Switzer silver stain (human and mouse)
A detailed protocol for this stain can be found at the NeuroScience 
Associates website: https:// www .neuroscienceassociates .com/ 
reference/ papers/ alzheimers -disease -pathology -silver -stain/ .
Thioflavin-S histology
A 1/12 series of sections spaced at 420-µm intervals were stained 
for thioflavin. Sagittal 35-µm sections were rinsed, mounted 
onto Superfrost Plus slides, and dried overnight. Sections were 
rehydrated in running tap water and incubated for 10–15 min in 
0.25% potassium permanganate followed by 5 min in 1% potas-
sium metabisulfite/1% oxalic acid, before staining in 0.02% 
Thioflavine-S (T1892; Sigma) for 8 min. Staining was differenti-
ated in 80% ethanol followed by running tap water. Sections were 
dehydrated through xylene and coverslipped with Permount.
Ubiquitin immunohistochemistry
A 1/12 series of sections were mounted onto Superfrost Plus 
slides and allowed to dry overnight. Slide-mounted sections were 
rehydrated in TBS before undergoing antigen retrieval in 10 mM 
sodium citrate buffer (pH 6.0) using a pressure cooker (Duo; 
918060242; Fagor America). For this process, slides were placed 
into a metal slide tray and immersed in citrate buffer inside the 
cooker. Once closed, the cooker was set on high (15 psi) and heated 
on a Bunsen burner until the pressure indicator tripped. The 
cooker was allowed to heat for an additional 10 min on the burner, 
then was removed from heat and cooled to room temperature 
before opening (accelerated by placing the unit into ice water). 
Slides were then removed from the citrate buffer, rinsed in TBS, 
and immersed in TBS containing 0.1% Triton X-100 (TBST) plus 
0.9% H2O2 for 15 min at room temperature to inactivate endoge-
nous peroxidases. After peroxidase treatment, nonspecific bind-
ing was blocked for 1 h at room temperature with TBS containing 
5% normal horse serum before overnight incubation at 4°C with 
mouse anti-ubiquitin antibody (ab7254; Abcam) diluted 1:500 
in blocking solution. After several washes in TBS, slides were 
incubated for 2 h at room temperature with biotin-conjugated 
horse anti-mouse secondary antibody (PK-6102; Vectastain Elite 
ABC, Mouse IgG; Vector Laboratories) diluted 1:500 in blocking 
solution. Slides were then washed in TBS, followed by 30 min at 
room temperature in HRP-avidin conjugate diluted 1:50 in TBS. 
Sections were developed with diaminobenzidine (D4418; Sigma), 
dehydrated, and coverslipped with Permount.
Immunofluorescence (NAB61, synaptophysin, PSD95, LAMP1, 
TFEB, and REEP5)
A 1/12 series of sections were rinsed with TBS and blocked with 
TBST containing 10% normal goat serum for 1 h at room tempera-
ture before overnight incubation at 4°C with mouse anti-Aβ anti-
body NAB61 (gift of V. Lee, University of Pennsylvania, Philadel-
phia, PA), rabbit anti-synaptophysin (AB9272; Millipore), rabbit 
anti-PSD95 (ab18258; Abcam), mouse anti-LAMP1 (1D4B; Devel-
opmental Studies Hybridoma Bank), rabbit anti-TFEB (1:1,000; 
A303-673A; Bethyl Laboratories), or rabbit anti-REEP5 (14643-
1-AP; Protein Tech), each diluted 1:500 in blocking solution. 
After several washes in TBS, sections were incubated with Alexa 
Fluor 568–conjugated secondary antibody (A11004 for goat anti–
mouse; A11036 for goat anti–rabbit; Invitrogen) diluted 1:500 in 
block for 2 h at room temperature. Sections were washed with 
TBS before being counterstained for 8 min at room temperature 
with 0.002% thioflavin-S diluted in TBS. After two 1-min washes 
in 50% ethanol followed by several washes in TBS, sections were 
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mounted on Superfrost Plus slides and coverslipped with Vecta-
shield mounting medium (H1400; Vector Laboratories).
Quantification of amyloid burden, synapse area, and 
dystrophic neurites
All imaging was performed with an Axio Imager Z1 microscope 
(Zeiss) using Zen 2012 software v.1.1.2.0. Bright-field and immu-
nofluorescent image mosaics were acquired by sequential scan-
ning with a motorized stage, stitched, and exported as tiff files. 
Sections stained for Campbell–Switzer silver, NAB61, thiofla-
vin-S, ubiquitin, and LAMP1 were quantified in Matlab (v.8.6 
R2015b; MathWorks). Automated color thresholds were used 
to distinguish signal from background across the entire stained 
section and quantified as a percentage of area within a manu-
ally outlined region of interest (cortex or hippocampus). Four to 
five sections spaced at 420-µm intervals were measured for each 
animal. The Matlab code for this analysis is publicly available for 
download on the Matlab File Exchange (https:// www .mathworks 
.com/ matlabcentral/ fileexchange/ 63987 -percent -area -roi).
Quantification of synapse area
For synaptophysin analysis, four nonoverlapping 40× fields cen-
tered on an isolated plaque were imaged from each of four tissue 
sections for each animal (16 fields per animal). A single optical 
plane was collected for each field in the red (synaptophysin) and 
green (thioflavin-S) channels using an Apotome structured illu-
mination device (Zeiss). A custom Matlab script was written for 
analysis. Each color channel was first converted to binary sig-
nal. The thioflavin image was used to outline the plaque using 
binary boundary detection. The code then dilated this boundary 
by 10, 20, and 30 µm and applied the outlines onto the thresh-
olded red channel to compute the area of synaptophysin signal 
as a percentage of total area in each annulus. The Matlab code 
for this analysis is publicly available for download on the Mat-
lab File Exchange (https:// www .mathworks .com/ matlabcentral/ 
fileexchange/ 63971 -synaptophysinroidilation).
Immunoblotting
Frozen brain samples were prepared for Western blotting by 
sonication in five volumes of PBS containing 1× protease and 
phosphatase inhibitors (5892970001 and 04906845001; Sigma) 
then diluted with an equal volume of 2× concentrated RIPA 
buffer (1× PBS + 2% SDS + 1% NP-40 + 1% deoxycholate + 5 mM 
EDTA) and centrifuged at 16,100 g for 10 min at 4°C. For most 
immunoblots, 10 µl supernatant was mixed with an equal volume 
of 2× Laemmli buffer and denatured at 95°C for 5 min before 
being loaded onto 4–15% Tris-HCl gels (3450028; Bio-Rad). After 
electrophoresis, proteins were transferred to nitrocellulose 
membrane (Trans-Blot Turbo Transfer kit 1704271; Bio-Rad), 
blocked in PBS containing 0.1% Tween-20 (PBSTw) and 5% nonfat 
dry milk for 1 h at room temperature, and probed overnight at 
4° with one or more of the following primary antibodies: 6E10 
(1:5,000; 803001; BioLegend), TFEB (1:1,000; A303-673A; Bethyl 
Laboratories), p-s6s244/240 ribosomal protein (1:2,000; 5364; 
Cell Signaling Technology), and p-AKTs473 (1:2,000; 4060; Cell 
Signaling Technology), p-cofilin (1:1,000; 3311; Cell Signaling 
Technology), or GAP DH (1:5,000; AB2302; Millipore). Blots 
were washed several times with PBSTw, incubated for 3  h at 
room temperature with IRDye-conjugated secondary antibodies 
(926-32212, 926-32214, 926-32213, or 926-68075, each diluted 
1:10,000; LI-COR Biosciences), and imaged with an Odyssey Fc 
detection system. After imaging, blots for p-s6 ribosomal protein 
and p-AKT were stripped (928-40030; LI-COR Biosciences), 
reblocked, and reprobed for total s6 ribosomal protein (1:1,000; 
2217; Cell Signaling Technology), total AKT (1:1,000; 4691; 
Cell Signaling Technology), or total cofilin (1:1,000; 5175; Cell 
Signaling Technology). Densitometry analyses were performed 
using Image Studio Lite software v.5.2 (LI-COR Biosciences).
ELI SA
Frozen cortical samples were prepared for Aβ ELI SA by sequen-
tial biochemical extraction as described previously (Youmans 
et al., 2011). Cortical tissue from one hemisphere was sonicated 
in cold TBS containing 1× protease and phosphatase inhibitors 
(5892970001 and 04906845001; Sigma) at a ratio of 1 ml per 150 
mg tissue weight. The homogenate was centrifuged at 100,000 g 
for 1 h at 4°C, and the supernatant was collected as TBS-soluble 
extract. The pellet was resuspended to its original volume by 
pipetting in TBS containing protease and phosphatase inhibitor + 
1% Triton X-100 (TBSX) and mixed by gentle rotation at 4°C for 30 
min. The homogenate was centrifuged at 100,000 g for 1 h at 4°C, 
and the supernatant was collected as TBSX-soluble extract. The 
TBSX pellet was resuspended to its original volume by pipetting 
in 50 mM Tris-HCl, pH 6.8, containing 5 M guanidine hydrochlo-
ride and mixed by gentle rotation at room temperature overnight. 
The next day, samples were centrifuged at 16,000 g for 30 min 
at room temperature, and the supernatant was collected as the 
guanidine-soluble extract. All samples were stored at −80°C until 
use. Aβ levels were determined by end-specific sandwich ELI SAs 
using monoclonal antibody 2.1.3 (human Aβx-42 specific) and 
13.1.1 (human Aβx-40 specific) for capture, and HRP-conjugated 
monoclonal antibody Ab5 (human Aβ1-16 specific) for detection, 
modified from an earlier assay (Chakrabarty et al., 2015).
Microdialysis
Microdialysis was performed as described previously (Cirrito et 
al., 2003; Ulrich et al., 2013) using a 1-MDa molecular weight cutoff 
microdialysis probe. In brief, dox- and dox + Ab9–treated mice 
were continued on their respective therapies after completion 
of behavioral testing. The microdialysis guide cannula were 
stereotaxically implanted with the guide cannula tip (Eicom) 
at coordinates bregma −3.1 mm, 2.5 mm from midline 1.2 mm 
below the dura at a 12° angle. After surgery, mice recovered for 
24 h followed by insertion of a 1-MDa molecular weight cutoff 
microdialysis probe that was 2 mm in length (AtmosLM probe; 
Eicom). Mice had freedom of movement and ad libitum food and 
water. Artificial CSF containing 0.15% BSA was perfused through 
the microdialysis probe at a constant flow rate (inward rate, 
1.1 µl/min; outward rate, 1.0 µl/min). Microdialysis samples were 
collected every 60–180 min in a refrigerated fraction collector. 
After the final collection, samples were assayed for Aβx-40 and 
Aβx-42 by sandwich ELI SA using mouse anti-Aβ antibodies mHJ2 
or mHJ7.4 for capture, respectively, and biotinylated mHJ5.1 for 
detection (Fisher et al., 2016).
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Statistical analysis
Data were analyzed using one- or two-way ANO VA or t test where 
appropriate for values with approximately normal distribution. 
All ANO VA post hoc comparisons were conducted using Tukey 
testing. Datasets characterized by a nonnormal distribution were 
analyzed using Kruskal–Wallis testing followed by Dunn’s post 
hoc comparisons. Most statistical analyses and all graphs were 
created using Prism 6.0 (GraphPad). Bar graphs display group 
means ± SEM. Multivariate ANO VA analysis was performed in 
SPSS v.23. Correlation analysis and general linear modeling were 
performed using R (v.3.3.3; R Core Team, 2017) packages: effects 
(v.3.1.2; Fox, 2003), MASS (v.7.3.45; Venables and Ripley, 2002), 
RCM DR (v.2.3.2; Fox and Bouchet-Valat, 2017), sandwich (v.2.3.4; 
Zeileis, 2004), and car (v.2.1.4; Fox and Weisberg, 2011).
Online supplemental material
Fig. S1 shows that acute suppression of Aβ overproduction fails 
to reverse cognitive impairments in aged APP/TTA mice. Fig. S2 
shows histological analysis of plaque burden in the hippocam-
pus. Fig. S3 shows biochemical measurements of Aβ40, Aβ42, 
and total Aβ levels measured by ELI SA for each treatment group. 
Fig. S4 shows additional control experiments from behavioral 
testing. Table S1 provides detailed statistical outcomes for all 
quantitative comparisons performed in these experiments.
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